In the BPC model, a 4‐hydroxytamoxifen (4‐HT)‐inducible Cre recombinase is used for the melanocyte‐specific expression of mutant BRafV600E—a constitutively active protein serine kinase—and inactivation of the Pten phosphatase to produce primary cutaneous malignant melanomas [11]. This evidence concerns the gene PTEN and melanoma.